Decisions by the Annual General Meeting of Affecto Plc

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Decisions by the Annual General Meeting of Affecto Plc

Helsinki, 2014-04-10 11:40 CEST (GLOBE NEWSWIRE) -- AFFECTO PLC  --  STOCK EXCHANGE RELEASE  --  10 APRIL 2014 at 12:40

Decisions by the Annual General Meeting of Affecto Plc

The Annual General Meeting of Affecto Plc, which was held on 10 April 2014, adopted the financial statements for 1.1.-31.12.2013 and discharged the members of the Board of Directors and the CEO from liability.

Approximately 33 percent of Affecto's shares and votes were represented at the Meeting.

DIVIDEND

The Meeting decided that a dividend of EUR 0.16 per share be distributed for the financial year 2013. The record date of the dividend payment is 15 April 2014 and the dividend will be paid on 25 April 2014.

BOARD OF DIRECTORS AND AUDITOR

The Meeting decided that the number of members of the Board of Directors is six. Aaro Cantell, Magdalena Persson, Jukka Ruuska, Olof Sand, Tuija Soanjärvi and Lars Wahlström were elected as members of the Board of Directors. In the organization meeting of the Board of Directors Aaro Cantell was elected Chairman of the Board and Jukka Ruuska as Vice-Chairman.

The Meeting decided that the monthly fees of the members of the Board of Directors shall be as follows: EUR 1,800 for the members, EUR 2,500 for the Vice-Chairman and EUR 3,200 for the Chairman. A fee of EUR 250 shall be paid for participation in Committee meetings, save for meetings of the Nomination Committee. The monthly remunerations for the entire term will be paid in August 2014 so that 60 % of the remuneration will be paid in cash and 40 % will be paid in the company's shares. The share component of the remuneration can be paid by issuing new shares, conveying own shares held by the company or acquiring shares based on the authorisations given to the Board of Directors by the Annual General Meeting. The share component of the remuneration will be paid primarily by acquiring shares through public trading. If the term of a member of the Board of Directors expires prior to payment of the monthly remunerations, the accumulated remuneration will be paid in cash during the month following the expiry of the term.

KPMG Oy Ab was elected auditor of the company with Reino Tikkanen, APA, as auditor in charge.

NOMINATION COMMITTEE

The Meeting approved the Board's proposal for appointing a Nomination Committee to prepare proposals concerning members of the Board of Directors and their remunerations for the following Annual General Meeting. The Nomination Committee will consist of the representatives of the three largest registered shareholders and the Chairman of the Board of Directors, acting as an expert member, if he/she is not appointed representative of a shareholder. The members representing the shareholders will be appointed by the three shareholders whose share of ownership of the shares of the company is largest on 31 October preceding the Annual General Meeting.

AUTHORISATIONS OF THE BOARD OF DIRECTORS

The Annual General Meeting approved the Board's proposals for the authorisations of the Board of Directors.

Authorisation to decide to issue shares

The Annual General Meeting decided to authorise the Board of Directors to decide upon the issuing of new shares and upon the conveying of the company's own shares held by the company in one or more tranches. The share issue may be carried out as a share issue against payment or without consideration on terms to be determined by the Board of Directors and in relation to a share issue against payment at a price to be determined by the Board of Directors.

The authorisation includes also the right to issue option rights and special rights, in the meaning of chapter 10 section 1 of the Companies Act, which entitle to the company's new shares or the company's own shares held by the company against consideration.

A maximum of 4,200,000 shares may be issued, of which a maximum of 2,100,000 can be own shares held by the company.

The authorisation comprises the right to deviate from the shareholders' pre-emptive subscription right provided that the company has a weighty financial reason for the deviation in a share issue against payment and provided that the company, taking into account the interest of all its shareholders, has a particularly weighty financial reason for the deviation in a share issue without consideration. Within the above mentioned limits, the authorisation may be used e.g. in order to strengthen the company’s capital structure, to broaden the company’s ownership, to be used as payment in mergers and acquisitions or when the company acquires assets relating to its business, for payment of the Board of Directors' remuneration and as part of the company’s incentive programmes. The shares may also be conveyed in a public trading. Shares may also be subscribed for or own shares may be conveyed against contribution in kind or by means of set-off.

The authorisation includes the right to decide upon a share issue without consideration to the company itself so that the amount of own shares held by the company after the share issue is at most one-tenth (1/10) of all shares in the company. Pursuant to chapter 15 section 11 subsection 1 of the Companies Act all own shares held by the company or its subsidiaries are included in this amount.

The authorisation replaces the authorisation resolved on by the Annual General Meeting on 9 April 2013 registered on 16 April 2013. The authorisation shall be in force until the next Annual General Meeting, however, not longer than until 30 June 2015.

Authorisation to decide to acquire the company's own shares

The Annual General Meeting decided to authorise the Board of Directors to decide upon the acquiring of the company's own shares with the company's distributable funds in one or more tranches on the terms set forth below. The acquisition of shares reduces the company's distributable non-restricted shareholders' equity.

The company's own shares may be acquired in order to strengthen the company's capital structure, to be used as payment in mergers and acquisitions or when the company acquires assets related to its business, for payment of the Board of Directors' remuneration and as part of the company’s incentive programmes in a manner and to the extent decided by the Board of Directors and to be transferred for other purposes or to be cancelled.

A maximum of 2,100,000 shares may be acquired.

The company's own shares may be acquired in accordance with the decision of the Board of Directors either through a public trading or by a public offer at their market price at the time of purchase. As the acquisition takes place in public, neither the order of acquisition nor the effect of the acquisition on the distribution of ownership and voting rights in the company nor the distribution of ownership and votes among persons belonging to the inner circle of the company is known in advance. The Board of Directors shall decide upon all other matters regarding the acquisition of own shares.

The authorisation replaces the authorisation resolved on by the Annual General Meeting on 9 April 2013. The authorisation shall be in force until the next Annual General Meeting, however, not longer than until 30 June 2015.

AFFECTO PLC Board of Directors

www.affecto.com

         Additional information:          Chairman of the Board, Aaro Cantell, tel. +358 400 706 072          SVP, M&A, IR, Hannu Nyman, tel. +358 205 777 761

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 938

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 240

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 490

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 188

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 150

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 462

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 235

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 289

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 309

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 261

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Sonic Partners with Obsessed Garage for Home Garage Solutions

Updated Category News Views 147

Sonic Teams Up with Obsessed Garage to Transform Home Garages Sonic, a front-runner in delivering high-quality tool solutions and equipment, has recently announced an exciting partnership with Obsessed Garage. This collaboration aims to cater to home garage enthusiasts who demand tools and storage solutions that match the quality standards utilized by professionals in the...

Continue Reading
Investors of Sun Communities, Inc. Urged to Act Before Deadline

Updated Category News Views 167

Important Update for Sun Communities, Inc. Investors There is a significant call to action for investors of Sun Communities, Inc. as a class action lawsuit has been filed against the company, urging those affected to act promptly. This is a crucial moment for investors who purchased securities from the company during a specific period. Legal representation is being...

Continue Reading
XOMA Stock Reaches New Heights: Key Developments and Insights

Updated Category News Views 67

XOMA Stock Performance Overview XOMA Ltd's stock has recently made headlines by reaching a remarkable 52-week high, with shares trading at an impressive $30.49. This achievement not only signifies a significant milestone for the company but also highlights a robust year-over-year growth that can't be overlooked. Investors have observed a substantial increase of 73.82% in...

Continue Reading
Evolv Technologies Faces Turmoil with Executive Departures

Updated Category News Views 230

Evolv Technologies Faces Turmoil with Executive Departures Evolv Technologies Holdings (NASDAQ: EVLV) is navigating turbulent times following the resignation of its Chief Financial Officer, Mark Donohue. His departure comes amid serious allegations of improper revenue recognition practices that have raised questions about the company's integrity and financial health....

Continue Reading
Editas Medicine: Financial Insights and Market Strategies Revealed

Updated Category News Views 56

Editas Medicine Maintains Price Target Amidst Financial Developments Recently, Leerink Partners reaffirmed a Market Perform rating for Editas Medicine (NASDAQ: EDIT), keeping a price target steady at $8.00. This decision comes closely after the company announced a substantial financing agreement with DRI Healthcare Trust. Under this agreement, Editas is set to receive an...

Continue Reading